Aquestive Therapeutics announced its Q1 2026 financial results, highlighting a 66% revenue increase to $14.4 million and a reduced net loss of $8.1 million. The company reaffirmed its plan to resubmit the Anaphylm (dibutepinephrine) sublingual film NDA to the FDA in Q3 2026 after aligning on study designs to address prior FDA concerns. Additionally, Aquestive completed a phase 1 study for AQST-108 topical gel with no safety issues and secured a $150 million debt facility to strengthen its financial position and support future growth. The company is advancing regulatory submissions globally and expanding its commercial infrastructure in preparation for potential product approvals.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Gold and silver prices are under pressure ahead of key U.S. retail sales data that could influence Federal Reserve interest rate decisions. Central banks, led by Poland and China, continue to boost gold reserves, adding 41 tonnes in May, supporting l...
